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Abstract
Poor adherence to efficacious cardiovascular related medications has led to considerable
morbidity, mortality, and avoidable health care costs. This paper provides results of a recent think
tank meeting in which various stakeholder groups representing key experts from consumers,
community health providers, the academic community, decision-making government officials
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(FDA, NIH, etc), and industry scientists met to evaluate the current status of medication adherence
and provide recommendations for improving outcomes. Below, we review the magnitude of the
problem of medication adherence, prevalence, impact, and cost. We then summarize proven
effective approaches and conclude with a discussion of recommendations to address this growing
and significant public health issue of medication non adherence.
Introduction
Medications are the primary tools used to prevent and effectively manage chronic illness;
however, despite their importance and known benefit, appropriate medication use remains a
challenge for both patients and providers. Patients frequently do not adhere to essential
medications, resulting in poor clinical outcomes, increased cost of care, and deleterious
consequences for workforce productivity and overall public health. 1 Half of the 3.2 billion
annual prescriptions dispensed in the United States are not taken as prescribed. 2 Numerous
studies have shown that patients with chronic conditions adhere only to 50-60% of
medications as prescribed despite evidence that medical therapy prevents death and
improves quality of life. 3-8
Estimates are that approximately 125,000 deaths per year in the United States are due to
medication non-adherence 9 and between 33 and 69 percent of medication-related hospital
admissions in the U.S. are due to poor adherence.2 While some of the relationship between
poor adherence and poor outcome is due to confounding factors, 10 the lost opportunity for
effective therapies to improve health is staggering. For example, cardiovascular medications
alone are estimated to be responsible for half of the 50% reduction in mortality from
coronary heart disease over the past 20 years. 11 Yet actual achievement of these
cardiovascular benefits is lost due to high rates of non-adherence in real-world settings. In
fact, the true rate of non-adherence may be higher as patients with a history of non-
adherence are likely underrepresented in trials outcomes research.
The consequences of medication non-adherence are not only poor clinical outcomes but also
unnecessary health care costs. The total cost estimates for non-adherence range from
$100-300 billion each year, and include both direct and indirect costs. 12-16 As an example
of the cost benefit of medication adherence, estimates are that for every additional dollar
spent on adhering to a prescribed medication, medical costs would be reduced by $7 for
people with diabetes, $5.10 for people with high cholesterol, and $3.98 for people with high
blood pressure. 17 Failure to identify and remediate poor adherence often results in
intensified pharmacotherapy with increased doses of medication – thus increasing the
overall cost of treatment, the risk of adverse effects,18 physician frustration, 19
misdiagnoses, and in more extreme situations, unnecessary treatment and exacerbation of
disease or fatality. 20, 21 Non-adherence also increases the cost-burden for informal, family
caregivers 22, 23 and leads to other undesirable outcomes, including lost work productivity
for patients and/or family caregivers.24 Understanding these multiple ‘cost drivers’ is
important for understanding the true cost of medication non-adherence.
Clear alignment exists among stakeholders, including patients, providers, policy makers, and
payors, to improve medication adherence. The Institute of Medicine reported
“Pharmaceuticals are the most common medical intervention, and their potential for both
help and harm is enormous.” Ensuring that the American people get the most benefit from
advances in pharmacology is a critical component of improving the national health care
system.” 25 A recent World Health Organization report states that because the magnitude of
medication non-adherence and the scope of these sequelae are so alarming, more health
benefits worldwide would result from improving adherence to existing treatments than from
developing new medical treatments. 1
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In response to the growing need to improve medication adherence, representatives of various
stakeholder groups representing key experts from consumers, community health providers,
the academic community, decision-making government officials (FDA, NIH, etc) and
industry attended a two day meeting to evaluate the current status of medication adherence
and provide recommendations for policy change to improve medication adherence and
related clinical and financial outcomes on a national scale. Our goals were to propose
strategies to raise national awareness of the adverse consequences of non-adherence; to
propose practical strategies for disseminating evidence-based approaches in real-world
clinical settings; and to delineate a broad role for electronic health information technology in
which connectivity of patient, provider, pharmacy and health system data could be
effectively used to generate important quality metrics for supportive monitoring and
management of medication information.
Definition and Measurement
Medication adherence refers to the extent to which patients follow provider
recommendations about day-to-day treatment with respect to the timing, dosage, and
frequency. 26 It may be defined as “the extent to which a patient acts in accordance with the
prescribed interval, and dose of a dosing regimen.” 26 Medication persistence refers to the
duration of medication-taking, and defined as “the duration of time from initiation to
discontinuation of therapy.” 26 The World Health Organization recognizes two distinct
categories of non-adherence, preventable (e.g., patient forgets, misunderstands) and non-
preventable (e.g., life-threatening side effects), and recommends targeting tailored treatment
interventions for the former. 17 A summary of these evidence-based reasons for non-
adherence and non-persistence are listed in Table 1.
Review of Medication Adherence Interventions and Programs
Interventions to improve adherence with prescribed medications are more successful for
short-term treatments than for long-term, chronic illness management 27 For long-term
treatments, 36 of 83 interventions reported in 70 randomized clinical trials (RCTs) were
associated with improvements in adherence, but only 25 interventions led to improvement in
at least one treatment outcome (Table 2). Almost all of the interventions that were effective
for long-term care were complex, including combinations of more convenient care,
information, reminders, self-monitoring, reinforcement, counseling, family therapy,
psychological therapy, crisis intervention, manual telephone follow-up, and supportive care.
For short-term treatments, 4 of 10 interventions reported in nine RCTs showed an effect on
both adherence and at least one clinical outcome, while one intervention reported in one
RCT significantly improved patient adherence, but did not enhance the clinical outcome.
Two problems with existing adherence interventions are clear. First, even the most effective
interventions did not lead to large improvements in adherence and treatment outcomes. As
reported in a recent meta-analysis of adherence interventions, adherence was improved only
by approximately 4 to 11% by most interventions. 28 Most interventional trials are focused
on a single medication or a particular disease area. In reality, the majority of patients take
multiple medications for multiple medical problems.29 Tailored interventions that provide a
menu-driven, patient-centered approach 30, 31 address adherence for many concomitant
medications and conditions, however interventions continue to be developed using a single
disease-focused approach. Given the narrow focus and small effect size, translation of
adherence interventions to large scale, real-world settings is likely to be unsuccessful,
particularly without the additional staffing to oversee intervention delivery and follow up, as
is available in clinical trials. In the short term, simple and scalable adherence strategies
should be more broadly used until they can ultimately become part of successful
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multifaceted and tailored interventions. Simple adherence strategies that result in even small
effect size at the individual level, when broadly implemented on a population level, may
provide substantial cumulative public health benefit by significantly leveraging therapeutic
efficacy. A recent retrospective analysis using Walmart pharmacy dispensing data from
more than 3 million individuals found such scalable results when calendarized blister
packaging was introduced at pharmacy for once-daily solid oral dose cardiovascular
medication. 32
A second problem with existing adherence interventions is the external or provider-driven
orientation of interventions. The dominating provider perspective also poses a barrier to
translation of these results in real-world settings. Providers have little control over actual
adoption of daily medication-taking behaviors, and interventions that facilitate a trusting
relationship and open communication are more likely to take hold. Evidence suggests that
there is a lack of accounting for patients’ perspectives, an omission of data on patient and
healthcare providers’ relationships, and a lack of focus on shared decision-making. 33, 34
The Institute of Medicine has asserted that “patient centered care” is 1 of the 6 pillars of
quality health care, yet strategies to incorporate shared decision-making into medication
adherence interventions still fall short. Most interventions strive to attain patient adherence
to an evidence-based medication target which may or may not be consistent with a more
patient-centered approach focused on the role of medications in the context of the patient’s
daily life. Achievement of the patient’s goals for treatment, established jointly between
patients, family and providers, are rarely the primary endpoint or objective of current
adherence interventions. 35, 36 Interventions are needed to enhance patient involvement,
facilitate the identification and self-administration of medications, improve patients’
medication-taking skills and behaviors, and improve self-monitoring and feedback to both
patients and providers regarding their medication use 37.
Although publications focusing on medication adherence have increased, there are limited
recommendations available to improve medication adherence beyond simplifying patients’
regimens when possible and providing frequent, timely reminders to take and/or refill
medication prescriptions. 38 Thus, compared with the many thousands of trials for the
efficacy of individual drugs, there are only a handful of rigorous trials of drug adherence
interventions and these provide little evidence that medication adherence can be improved,
either consistently or over extended periods of time, as is required for management of
chronic illness. To further complicate this research area, retrospective analyses of pharmacy
claims data, a major source of currently-available adherence data, if appropriately conducted
with rigorous analyses, can only provide insight into persistence outcomes and cannot
address other measures of adherence. 26 Therefore, prospective research is required to fully
understand the effects of various interventions on adherence.
In general, many of the interventions for long-term medications tend to be exceedingly
complex, labor intensive, costly, and only loosely patient-centric in design. In addition,
questions remain as to how to optimally target interventions to patient likely to benefit and
hot feasibly carry out and sustain interventions in non-research settings, particularly in the
current era of cost containment and staff reductions. However, given that the factors
influencing medication adherence are many and varied, it is clear that multifaceted, tailored
interventions will be necessary to improve self-administration of medication. 39, 40
Practical, Evidence-Based Strategies for Clinical Practice
We set out to identify practical strategies to address the complex problem of medication
adherence in clinical settings. Our assumptions included the following basic beliefs, 1) that
proven strategies should be considered and integrated in a tailored, multi-pronged fashion
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for each case; 2) that medication adherence is a shared goal for which all members of the
health care team, the patient, family, providers, community liaisons, and health policy-
makers, have an inherent role and responsibility; and 3) that while larger, national drivers of
palpable change (e.g., quality indicators for adherence-related outcomes, national systems
and standards for health information technology) were forthcoming, we might preemptively
succeed through strategic, participatory action at the local level in our own clinical practice
arenas.
Assumption #1: A multifaceted, tailored approach is most effective
Among the interventions found to be most effective in randomized clinical trials, successful
interventions address known barriers, regardless of whether the barrier is owned by the
patient, provider, community healthcare system or governmental agency. 2, 27 Given that
there have been over a 100 factors observed to be associated with medication
nonadherence, 41 the importance of tailoring material to individuals’ needs and using a
multi-faceted approach becomes more apparent. 42 Known barriers can be characterized in
three ways: 1) those that address knowing what to do and why (health literacy), 2) those that
address doing the skills necessary to accomplish medication-management in the context of
everyday life (behavioral change), and 3) system or administrative barriers related to access
and fragmentation of care. Thus, the most effective interventions use a combination of
approaches and address these barriers.
Health Literacy Interventions—Health literacy refers to the ability to read, understand
and use information to make decisions for treatment. 43 This includes both the context (or
setting) in which health literacy demands are made and the skills that people bring to that
setting. 44 For example, patients interpret visual media, graphics, written pharmaceutical
labeling or one-on-one verbal instructions differently depending on their health literacy
skills, learning style, and ability to interpret and synthesize information. Inadequate health
literacy among patients and family caregivers is prevalent and directly related to medication
non-adherence.45 The Institute of Medicine estimated that over 90 million adult Americans
lack the literacy skills to understand, question, and make informed decisions in the current
health care environment.46
Practical strategies to address health literacy begin with an assessment of the patient’s ability
to read written information and understand the reasons for the medication and the proper
‘dose’, ‘timing’ and ‘duration’ for taking the medication. Short, validated
questionnaires47, 48 that assess health literacy can be used at clinic intake or during an acute
admission.49
When health literacy is low, steps can be initiated to meet the patient’s needs and improve
the quality of care. Interventions for patients with low health literacy include using picture-
based, easy-to-understand health education materials; explaining medication drug labeling in
lay terms, using video presentations; creating an empowering environment for patients and
caregivers to ask questions and post concerns; and, offering communication training for all
providers involved in the process. Identification of opportunities to include a spouse or
family member in the medication information process improves effectiveness.50 In addition,
using demonstration-based methods such as the “teach back”, asking patients or caregivers
to repeat key information in their own words, ensure that patients and families have heard
and processed the information appropriately. However, despite many tools, a systematic
review of interventions for limited literacy found mixed results and methodological
limitations that prevented definitive conclusions about efficacy of these types of
interventions.51
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As a general rule for all literacy levels, clinicians should prioritize and limit the number of
key points discussed during each interaction to three or fewer. 52 People comprehend more
and make better-informed decisions when the most important information is presented first,
is easy to evaluate and requires less cognitive effort. 53 For example, Shrank, et al 54
summarized that when optimizing content, patients prefer information about the indication
for the medication, expected benefits, duration of therapy, and a thorough list of potential
adverse effects, in addition to typical information identifying the drug’s name, directions for
use, and warnings. Yet the feasibility of delivering even basic information in a clinical
setting is questionable,55 and the impact of wide dissemination of information on potential
side effects through direct-to-consumer advertising – like myalgia from statins – could have
a negative impact on adherence. More research is needed to understand the net impact of
this type of information.56
Federal requirements for drug labeling contribute to health literacy barriers. Unfortunately,
the medication labels and information leaflets that patients rely on for pertinent drug
information are often difficult for patients to understand. A growing body of research, for
example, has found that patients frequently misinterpret prescription drug labels. 57
Recently, both the NIH and the FDA have focused attention on better understanding the
related topics of adherence and product naming, labeling, and packaging. In April, 2010, the
NIH issued a Request for Information: Priorities for the NIH Adherence Research Network
(NOT-OD-10-078) “Current and Emerging Priorities in Adherence Research that Offer the
Greatest Potential for Improving the Nation’s Health and Well-Being.” In July of 2010, the
U.S. Food and Drug Administration (FDA) issued a federal register notice and conducted a
public workshop on “Developing Guidance on Naming, Labeling, and Packaging Practices
to Reduce Medication Errors” (Federal Register - April 12, 2010 (Volume 75, Number 69,
Page 18514-18516) (Docket No. FDA-2010-N-0168) and is working towards issuing that
guidance in the near future. FDA recently announced plans to create a new framework for
the development and distribution of patient medication information (PMI) to be provided to
patients who are prescribed drug products. Under the current system, patients may receive
several types of information, developed by different sources that may be duplicative,
incomplete, or difficult to read and understand. PMI is expected to replace Consumer
Medication Information (CMI), Patient Package Inserts (PPI), and Medication Guides
(MGs) with a single page document that provides concise, clear, and consistent information
in a standard format. The FDA has solicited and continues to solicit stakeholder input for the
new PMI Initiative. In addition, through a cooperative agreement with the Engelberg Center
for Health Care Reform at Brookings, a series of expert meetings and public workshops
were convened to discuss the design, content and format of the proposed single-page PMI
prototypes, distribution and patient access to PMI, and how to design pilots for the
implementation, distribution, and evaluation of standardized PMI (Federal Register-August
27, 2010 (Volume 75, number 166, Page 52765-52768, http://www.brookings.edu/events/
2011/0223_PMI_pilots.aspx; http://www.brookings.edu/events/
2010/1012_patient_medication_information.aspx#,)
In summary, medications and related instructions for use are complex. Teaching strategies
that employ effective communication techniques between patients and providers, and among
providers, may be the single most important intervention to reduce medication
misinformation and poor adherence related to low health literacy. 58-60
Behavioral Interventions—In addition to understanding what to do and why, patients
need behavioral skills to facilitate adoption and integration of medication-taking into
everyday life. Family caregivers, providers, healthcare systems and policy-makers must
facilitate and support behavioral changes. 41, 61 Behavioral strategies that improve
medication adherence include self-monitoring (e.g., use of diaries, logs, calendarized
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packaging, electronic reminders, triggers and alerts), positive reinforcement (e.g., digital
feedback mechanisms, trending, incentives and rewards), and accountability partnering (e.g.,
provider-patient contracting, web-based support groups). 62, 63
Self-monitoring, a component of medication self-management, is the process of watching
and tracking one’s own medication regimen for adherence, consistency, problems or
difficulties in order to successfully employ correction or change strategies. Patients who
effectively self-monitor often use situational cues to integrate medication-taking into their
usual daily routine. Cues can be linked to activities, such as meals or bedtime. An example
of a physical cue is placing the medication container prominently by a toothbrush or lunch
box.
Interactive voice response (IVR) tele-monitoring interventions have been shown to improve
adherence to medications for chronic diseases and intermediate outcomes (e.g., diastolic
blood pressure and hemoglobin A1C). 64-66 For patients, electronic reminders have
improved prescription refill and adherence to dosing schedules, but these results have been
difficult to sustain over time.67 Computerized alerts to care providers in the outpatient
setting have improved medication reconciliation rates and safety-related processes of
care. 68, 69 An automatic alert to pharmacists about potentially inappropriate medications
(e.g., amitriptyline and diazepam) for elderly patients led to significant decreases in the
dispensing of these medications. 68 In addition, an automated alert to care providers
increased the ordering of laboratory tests to monitor for potential adverse drug effects. 69
Industry-based efforts to improve timing of reminders and reinforcement-type cues have
been introduced and tested in the form of calendar-based blister packaging. Especially when
used in combination with education and other reminder strategies, the calendar-based blister
packs have been shown to improve medication adherence. 70 The first large-scale
pharmacoepidemiologic analysis of the effect of medication packaging has refocused
attention to relatively simple approaches, such as “reminder” packaging, that can be widely
implemented for once-daily medications take for chronic diseases. Calendarized child-
resistant blister packaging was associated with modest improvement in prescription refill
adherence and persistence, and significantly higher probability of patients having filled
medication for at least 80% of days in the year. 71
Assumption #2: Medication Adherence as a Shared Goal and Responsibility
Shared goals are mutually agreed upon priorities and objectives for medication selection,
management and medication-taking behaviors. Communication or reciprocal flow of
information among patients, caregivers and providers is needed to improve medication
adherence. Opportunities to close communication gaps occur at each step of the process. For
example, a medication prescription or prescription change is dependent on coordinating the
multidisciplinary provider tasks of assessing medication-taking preferences, barriers and
capabilities, prescribing, educating, and filling a prescription correctly. In addition, patient
and family caregiver tasks such as obtaining the medication, adhering to the prescribed
schedule, and reporting a response to the appropriate provider must be coordinated.
Recommendations to improve medication-related health communication include employing
patient-centered communication using clear health communication techniques, and
confirming a common understanding of goals and priorities using regular review and
reinforcement of information.50, 72
Maintenance of many medication-taking behaviors declines over time, posing yet another
barrier to sustainability of effective interventions. Reiterative, positive reinforcement,
frequent feedback and regular follow-up are essential to ensure adequate adherence over
time. 73, 74 Future research must focus more on understanding what constitutes sufficient
and effective education and communication of medication-related information between the
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patient and the care provider in clinical practice. Ongoing studies of person-centered
strategies and patients’ perception of information about the medication may serve to
redesign and refocus adherence promoting initiatives in such a way as to improve
adherence. 75
Assumption #3: Evaluate with iterative monitoring and ongoing quality metrics
Both patients and providers benefit from regular, ongoing feedback regarding performance
in achieving commonly established treatment goals. Some patients benefit from maintaining
a daily medication record of each dose taken or missed with relevant comments. The
healthcare provider can then review this medication diary over the telephone or at the next
clinic visit with the patient. Additional benefits include identifying potential predisposing
factors for a relapse into old behavior and setting appropriate and realistic goals for new
behaviors. Use of the ACE-ME model, which emphasizes the collaborative approach to
medication adherence, or a similar clinically useful strategy is recommended. The acronyms
represents the following steps: Assessment of medication management capacity, including
cognitive skills; Collaboration on a strategy that creates and maintains a plan tailored to the
patients needs; Education to explain the effects of medication and articulate why a regimen
is important; Monitoring to see how the plan is implemented. This should be evaluated at
every visit. Evaluation to see when the plan is not working and need to begin another ACE
cycle. 76
Timing of Evaluation and Predictable Peaks and Troughs—Patient adherence is
greatest 5 days prior and 5 days post appointment with health care providers and usually
tapers off significantly within 30 days – the so called “white coat adherence.” 77 Thus,
improving medication adherence in the context of chronic diseases is dependent on timing of
evaluation, open, ongoing communication, and sensitivity to predictable peaks and troughs
in adherence patterns. Providing a one month supply of all new medications to the patient
prior to discharge has been adopted by some healthcare systems such as Geisinger as an
effective approach to no-fill prescription rates.
Successful intervention programs ideally can preemptively identify who and when
individuals will run into adherence problems. E-script, for example, has developed an
algorithm that can predict who is likely not to refill a prescription versus waiting three
months to use a medication refill algorithm to calculate pill refill rates. In addition, patients
can encounter difficulties filling or taking prescription medications at a number of loci in the
administration process, and specific analyses evaluating barriers at each point may help to
better target interventions. 78 For those individuals who receive medications that are directly
tied to electronic medical records, future work may need to explore the use of other
screening and predictive models of medication non-adherence.
Communicating medication changes through medication reconciliation and improving the
frequency and capacity for communication around medication reconciliation has been well
described and evaluated in a number of community pharmacy-based projects. The
community pharmacist plays an important role in ensuring that drug therapy is appropriate
and that communication regarding changes in therapy occur among all key players,
including patients, providers and caregivers. 1 Direct pharmacy interventions such as
pharmacy CME developed by pharmaceutical manufacturers and more recently, packaging
manufacturers, can optimize pharmacist counseling time and efficiency during the
medication reconciliation process.
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System-Based Strategies at the National Level
Financial Incentives and Medication Adherence
For many patients on Medicare, the coverage gap in Part D is a financial challenge,
particularly for inexpensive medications. Sometimes, generic alternatives provided at low
cost by national chains like WalMart or Kmart can provide a solution. A number of studies
have examined the importance of copayments on medication adherence. Numerous studies
have shown a strong and consistent relationship between copayments and medication
adherence. 79 This has led to a movement, known as Value Based Insurance Design (VBID),
to reduce copayments for the most effective, high value medications. 80, 81 A host of
observational studies demonstrate that reducing copayments for highly effective chronic
therapies can substantially improve adherence. 81, 82 Moreover, studies suggest that when
physicians prescribe generic or lower-cost medications for patients, adherence improves. 83
Prospective, large-scale trials are underway to examine whether VBID can both improve
adherence and reduce downstream healthcare costs. 84
Others have posited that simply reducing copayments may not be sufficient, and have
proposed that providing financial rewards for better adherence may be even more effective
mechanism to promote behavior change. Volpp et al found a significant impact from
financial incentives to improve smoking cessation rates 85 as well as for promoting weight
loss. 86 While physician pay-for-performance has received substantial attention in the
medical literature, patient pay-for-performance is a concept that needs further research to
understand its long-term effectiveness and cost-effectiveness.
Role of Health Information Technology and Electronic Health Records
The ability to use electronic health records to systematically collect, organize, access,
analyze, and better understand health information is expected to transform the practice of
medicine.83 Health information technology (health IT) can improve the connectivity of
patient, provider, pharmacy, and health system data and is already used to generate
important medication management and monitoring quality metrics.
Electronic prescribing, and the potential to use health IT to capture and provide a notice
from the pharmacy to the prescriber when the prescription is filled (or not), provides a
significant opportunity to measure and improve medication adherence. When medication
information is shared electronically, prescribers have access to information that allows them
to assess a patient’s medication regime at the point of care and to identify non-adherence.
Electronic systems may also be able to notify a prescriber or pharmacist about refills, which
can help trigger an intervention to avoid a potential gap in medication use.
Health information exchange can facilitate medication reconciliation by providing a means
for health care providers to capture a patient’s complete medication list and for other
members of a care team to retrieve that information to reconcile medications across the care
continuum--during transitions of care, hospital admissions, and hospital discharge.
The Centers for Medicare & Medicaid Services (CMS) in the U.S. Department of Health
and Human Services provides incentives to encourage the “meaningful use” of certified
electronic health record technology (certified EHRs) by eligible professionals and eligible
hospitals. In order to receive incentive payments, CMS requires eligible professionals and
eligible hospitals to meet certain measures, some of which support improved medication
adherence, using certified EHRs. The Office of the National Coordinator for Health IT
(ONC), establishes standards and certification criteria for certified EHRs, which can then
enable professionals and hospitals to meet these measures. Some of the measures and the
related criteria for certified EHR functionality support efforts to improve medication
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management and medication adherence. For example, meaningful use Stage one includes
requirements to maintain active medication and allergy lists and to generate prescriptions
electronically for a specified percentage of patients. Stage one also includes an option for
provider to perform medication reconciliation for transitions of care. Additional meaningful
use criteria in stage one promote consumer empowerment by giving patients access to their
information, including discharge instructions and patient summaries. This could assist with
medication adherence by providing information to patients to help them understand the
prescribed medications and instructions for taking those medications.
Health IT has the potential to provide alerts and reminders to both providers and patients to
support medication adherence in the future. As more data becomes available about factors
that improve the likelihood of non-adherence, EHR functionality could use predictive
modeling to identify patients who are least likely to comply with medication regimens and
enable targeted intervention to improve compliance. While the evidence regarding health
IT’s role in interventions to improve adherence is quite thin, studies evaluating the role of
electronic reminders show promise. 84 Consumer eHealth tools, such as personal health
records and mobile phone applications, are being used to empower patients to play a more
active role in managing their medication. These tools may provide electronic reminders to
patients, allow patients to track their adherence and, in some instances, provide real-time
information back to the provider for intervention and/or targeted follow-up. This interactive
capability is important, since some literature suggests that patient engagement is associated
with improved treatment adherence. 84
National Consumers’ League – Efforts to Increase National Awareness
A large public health response to the problem of medication adherence is being led by the
National Consumers League (NCL) with a multi-year, research-based public education
campaign. The goal of the campaign, Script Your Future, is to raise awareness among
consumers and their family caregivers about the importance of taking medication as
prescribed as a vital first step toward better health outcomes. The campaign focuses on
patients affected by three chronic conditions – diabetes, respiratory disease, and
cardiovascular disease. It encourages patients and health care professionals to better
communicate about ways to improve medication adherence, and includes specific outreach
to health care professionals to support them with tools and resources to help patients be
more adherent. NCL has built a coalition of public and private stakeholders, including
representatives from government agencies, consumer and patient groups, professional
associations, business and labor, and adherence researchers, all of whom have a vested
interest in improving medication adherence to move this campaign forward. The campaign
includes coordinated national communications and targeted outreach efforts in six cities:
Baltimore, MD; Birmingham, AL; Cincinnati, OH; Providence, RI; Raleigh, NC; and
Sacramento, CA. The campaign, launched in May 2011, will continue for at least three
years.
The campaign will measure its impact – both nationally and in select target markets. Before
the campaign launch in May 2011 a baseline survey was conducted, nationally and in the six
target cities, to measure consumers’ awareness of medication adherence as a health issue.
The survey will be replicated at the end of the campaign and results compared. In addition,
the campaign’s evaluation working group will explore ways to measure changes in
medication adherence behavior resulting from the campaign and complementary
interventions.
The campaign consumer website is located at http://www.ScriptYourFuture.org, and the
health care professional website visit http://www.scriptyourfuture.org/hcp.
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Future Directions and Recommendations
There are both enormous challenges and opportunities in addressing the public health crisis
of medication adherence. The multifactorial basis for non-adherence calls for a multifaceted
solution. The first important theme in this think-tank meeting was that a large number of
interventions could, if effectively applied, have a large impact on adherence and thereby on
improving public health. An initial step is a common understanding of some of the key
issues among stakeholders including representatives from government (e.g., FDA, NIH,
CMS), industry (e.g., pharmaceutical companies, packaging companies), insurers (e.g., both
private and government), employers, health care providers, and patients prescribed
medications. A major deficiency has been the inability to routinely measure and track
adherence in standard practice. Electronic health systems provide an important opportunity
to address that gap, particularly with guidance from the Department of Health and Human
Services on defining meaningful use to include measurement and integration of tools to
improve adherence in the electronic health record.
A second recurring theme of the meeting was the ongoing need to assess and understand the
impact of various interventions, including the cost of interventions. Studying methods to
improve adherence has been identified as an area of interest for Medicare innovations
grants. Broad evaluation of practical interventions, like simply asking if patients are having
trouble taking their medications, offering pill organizers, and using automatic reminders
when prescriptions are not refilled on time, are feasible yet underutilized strategies.
Conclusion
In summary, if over 100 different factors have been identified as potential predictors of
medication adherence, one can’t expect ‘one size intervention, to fit all.’ We need to
examine alternative methods of implementing interventions in order to create an effective,
readily available and easy to use tool box for providers. Technology will increase in use and
will likely help many individuals, but development of technology needs continued input
from both patients and from providers on how to incorporate these advances into clinical
care. Related, further thought into reimbursement models for medication adherence and
related technology are needed. Equally important, funding must be made available to
formally study methods of intervention and dissemination of these methods. Thus, to these
ends, we are also proposing an ongoing alliance to continue to work together to frame the
problems related to medication adherence and share methods and successes for improving
optimal use of evidence based treatment.
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Table 1
Preventable and Non-Preventable Reasons for Discontinuation or Non-Adherence
Preventable Non-Preventable
Low health literacy (patient did not understand instructions) Serious mental illness (major depression; schizophrenia)
No-fill of first prescription identified Serious side effects (e.g., diarrhea, weight gain, sleeplessness)
“Non-responder” or no clinical evidence of effectiveness of the medication Serious adverse events (e.g., allergic reaction; renal toxicity)
Irregular refills obtained
Cost prohibitive for the patient
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Table 2
Common Barriers and Evidence Based Interventions
Barrier to Knowing What To Do or Why Clinical Strategy to Improve Adherence
Low health literacy
• did not understand instructions
• did not understand reason for
medicines
• did not understand relationship
between medicines and illness
• did not understand the expected
duration of use
• could not fill pill organizer correctly
• did not understand where or how (for
mail-in prescription refill) to obtain
medications, and at what frequency
• Too much information
• Use proven educational methods to give instructions:
– Written and verbal information at 3rd grade reading level
– Use pictures in addition to words
– Conduct a medication use skills check (e.g., teach – demonstrate –
repeat and playback methods for filling pillbox)
– Ask patient to watch a short video on his medications and how to
take them prior to leaving the office or while waiting
• Give instructions to a second person (spouse or significant other, or
community health worker)
• Present 2-3 key points only; send complete list of medications and instructions
in written, picture or audiovisual format
• Use community liaison or pharmacist to reinforce information at a later time
Poor communication • Engage clinic and provider staff in communication training
• Engage patients in using e-health diaries (or written versions available online)
to log concerns, side effects or symptom patterns
• AVOID the following:
– overwhelming the patient with too much information
– using jargon and technical terminology
– relying on words alone
– failing to assess patient understanding
Negotiate agreement with the medication plan • Simplify the dosing regimen
• Explore the patient’s activity and meal schedule, and preferences for dosing
schedules
• Altering the administration route
• Using electronic adherence aids (MEMS cap)
• Explore the patient’s beliefs about the medication and how it works for him
Barrier to Doing
No-fill of first prescription identified • Dispense to the patient the first week of medications at discharge or in clinic
• Identify a person to obtain medications for the patient following discharge /
clinic visit
• Discuss the patient’s desire/willingness to take the new medication
Irregular refills obtained / forgetfulness • Choose drug available in a calendarized blister-packaging
• Enroll patient in a frequent follow-up program to receive reminder triggers
from pharmacist
• Use multiple frequent reminder trigger systems with the patient, including cell
phone or home monitoring technology
• Include a caregiver in the communication for reminders
• Engage patient in an accountability partnership of his choice – contract, web-
based or community support group
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Barrier to Knowing What To Do or Why Clinical Strategy to Improve Adherence
• Obtain from pharmacy patient-based trends in fill-rate, and discuss feedback
with patient
Cost prohibitive for the patient • Select a different medication or a generic
• Identify a local low-cost drug program (e.g., Walmart, Target)
• Identify a payment program for non-generic drugs
“Non-responder” or no clinical evidence of
effectiveness of the medication
• Ask patient about medication-taking using a validated assessment tool
• Ask family caregiver or significant other
• Use a controlled short term monitor (e.g., medication diary, electronic capture
or MEMS cap) and re-evaluate drug response
Non-Preventable Discontinuation Clinical Strategy to Improve Adherence
Serious mental illness (major depression;
schizophrenia)
1 Attempt to treat mental health first; then resume other medication adherence /
interventions and monitoring
Side effects (e.g., diarrhea, weight gain,
sleeplessness)
1 Attempt to confirm drug-effect relationship
2 Alter medication choice (change drug class, change to new drug class)
3 Modify dose
Serious complications (e.g., allergic reaction) 1 Discontinue; change drug choice
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